ATE424560T1 - Marker für neuromyelitis optica - Google Patents

Marker für neuromyelitis optica

Info

Publication number
ATE424560T1
ATE424560T1 AT04812269T AT04812269T ATE424560T1 AT E424560 T1 ATE424560 T1 AT E424560T1 AT 04812269 T AT04812269 T AT 04812269T AT 04812269 T AT04812269 T AT 04812269T AT E424560 T1 ATE424560 T1 AT E424560T1
Authority
AT
Austria
Prior art keywords
marker
neuromyelitis optica
optica
neuromyelitis
nmo
Prior art date
Application number
AT04812269T
Other languages
English (en)
Inventor
Vanda Lennon
Thomas Kryzer
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE424560T1 publication Critical patent/ATE424560T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
AT04812269T 2003-11-25 2004-11-24 Marker für neuromyelitis optica ATE424560T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/723,180 US7101679B2 (en) 2003-11-25 2003-11-25 Marker for neuromyelitis optica

Publications (1)

Publication Number Publication Date
ATE424560T1 true ATE424560T1 (de) 2009-03-15

Family

ID=34592190

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04812269T ATE424560T1 (de) 2003-11-25 2004-11-24 Marker für neuromyelitis optica

Country Status (9)

Country Link
US (5) US7101679B2 (de)
EP (1) EP1700120B1 (de)
JP (1) JP4538464B2 (de)
CN (1) CN1910456B (de)
AT (1) ATE424560T1 (de)
DE (1) DE602004019812D1 (de)
ES (1) ES2320006T3 (de)
IN (1) IN2014DN05011A (de)
WO (1) WO2005051178A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101679B2 (en) 2003-11-25 2006-09-05 Mayo Foundation For Medical Education And Research Marker for neuromyelitis optica
US20070093673A1 (en) * 2005-10-24 2007-04-26 Andre Vachereau Boron-containing compounds, uses and preparation thereof
JP4273235B2 (ja) * 2006-06-01 2009-06-03 国立大学法人 新潟大学 アクアポリン４阻害薬
US8889102B2 (en) * 2007-09-20 2014-11-18 Mayo Foundation For Medical Education And Research Neuromyelitis optica autoantibodies as a marker for neoplasia
JP5117336B2 (ja) * 2008-09-18 2013-01-16 国立大学法人 千葉大学 多発性硬化症またはｎｍｏの検査マーカーの測定方法
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
GR1007341B (el) 2010-04-21 2011-07-05 ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΠΑΣΤΕΡ (κατά ποσοστό 40%), Διαγνωστικος προσδιορισμος
CN103154736B (zh) * 2010-05-13 2016-04-06 新泽西医科和牙科大学 用于检测和诊断神经变性疾病的诊断性自身抗体谱
DE102011011280A1 (de) 2011-02-15 2012-08-16 Euroimmun Medizinische Labordiagnostika Ag Diagnosekit sowie ein Verfahren zur Untersuchung einer menschlichen Patientenprobe auf das Vorhandensein von Neuromyelitis-optica-spezifischen Antikörpern
KR20140059168A (ko) 2011-04-21 2014-05-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 시신경 척수염 치료용 조성물 및 치료 방법
WO2013010003A1 (en) 2011-07-12 2013-01-17 University Of Medicine And Dentistry Of New Jersey Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease
AU2012326089A1 (en) * 2011-10-21 2014-05-01 The Board Of Regents Of The University Of Texas System Codon signature for neuromyelitis optica
EP2833140B1 (de) 2012-03-30 2018-05-09 Konica Minolta, Inc. Verfahren zum Nachweis von biologischem Material
US20150139981A1 (en) * 2012-05-21 2015-05-21 The Regents Of The University Of California Enzymatic modification of anti-aqp4 autoantibody for modulating neuromyelitis optica
CN102898513B (zh) * 2012-10-31 2016-03-16 徐俊 ELISpot视神经脊髓炎诊断试剂盒及其应用
WO2014154907A1 (de) * 2013-03-28 2014-10-02 Protagen Ag Verfahren zur diagnose von neuromyelitis optica
JP6764790B2 (ja) * 2014-05-19 2020-10-07 ザ・ジョンズ・ホプキンス・ユニバーシティー 視神経脊髄炎の治療に対する高可溶性アクアポリン−４細胞外ループペプチド免疫化
EP3146074A1 (de) * 2014-06-30 2017-03-29 Siemens Healthcare GmbH Diagnose von neuromyelitis optica gegen multiple sklerose mit mirna-biomarkern
CN104698190A (zh) * 2015-03-16 2015-06-10 中国人民解放军总医院 用于中枢神经系统脱髓鞘疾病的生物诊断标记物
US10098935B2 (en) * 2015-05-01 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Aquaporin tolerizing vaccines and methods of use thereof
EP3454920B1 (de) * 2016-05-13 2024-04-24 C. R. Bard, Inc. Peripher eingesetzter zentraler katheter für die pädiatrie
CN106318974A (zh) * 2016-08-29 2017-01-11 南方医科大学南方医院 细胞固定工艺及通过该工艺制备aqp4抗体检测试剂盒
KR101977843B1 (ko) 2017-02-16 2019-05-13 국립암센터 시신경척수염 및 다발성경화증의 선별을 위한 바이오마커 및 이의 이용
JP7067800B2 (ja) * 2017-04-12 2022-05-16 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用
KR102089042B1 (ko) * 2017-05-16 2020-03-13 서울대학교병원 보체불활성화법을 이용한 항-아쿠아포린 4 항체의 개선된 검출 방법
CN108998450A (zh) * 2018-08-08 2018-12-14 昆明医科大学第附属医院 引物、cDNA、载体、AQP4单克隆抗体及制备方法
CN110618264A (zh) * 2019-09-10 2019-12-27 南方医科大学 基于量子点聚苯乙烯微球检测抗aqp4抗体的方法
CN111272998A (zh) * 2020-01-09 2020-06-12 天津天海新域生物科技有限公司 一种同时检测中枢脱髓鞘自身抗体aqp4、mog和mbp的方法
WO2022155358A1 (en) * 2021-01-13 2022-07-21 Duke University Compositions for and methods of improving fluid flux in the brain
CN115232795B (zh) * 2021-07-22 2023-09-19 北京和合医学诊断技术股份有限公司 稳定表达aqp4-m23蛋白的细胞株及其构建方法、应用
CN113358881B (zh) * 2021-08-10 2021-11-30 首都医科大学附属北京天坛医院 用于nmosd预测或复发监测的生物标志物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37273A (en) * 1863-01-06 Improved canteen
US4708713A (en) * 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
US5258503A (en) * 1987-09-08 1993-11-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Autoantibody adsorbent and apparatus for removing autoantibodies using the same
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5214136A (en) * 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5218105A (en) * 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5741671A (en) * 1991-12-12 1998-04-21 The Johns Hopkins University Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1)
US5324638A (en) * 1992-05-13 1994-06-28 Sloan-Kettering Institute For Cancer Research Brain transcription factor, nucleic acids encoding same and uses thereof
DE4227695C1 (de) * 1992-08-21 1993-10-07 Fresenius Ag Zentrifuge zum Auftrennen von Blut in seine Bestandteile
US5676644A (en) 1995-06-07 1997-10-14 Cobe Laboratories, Inc. Extracorporeal blood processing methods and apparatus
WO1997017369A2 (en) * 1995-11-09 1997-05-15 Trustees Of Boston University Dna comprising a neuron-specific transcriptional promoter and its use in a gene therapy vector
EP1147011A1 (de) 1998-11-25 2001-10-24 Amarillo Biosciences, Inc. Durch alpha-interferon vermittelte steigerung der aquaporin expression
US20040014087A1 (en) 1999-06-01 2004-01-22 Incyte Corporation Molecules for diagnostics and therapeutics
US6409726B1 (en) * 1999-11-08 2002-06-25 Alan G. Ellman Electrosurgical instrument for ear surgery
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20040048253A1 (en) 2001-02-21 2004-03-11 Panzer Scott R. Molecules for diagnostics and therapeutics
US7251568B2 (en) 2001-04-18 2007-07-31 Wyeth Methods and compositions for regulating bone and cartilage formation
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20040115629A1 (en) 2002-01-09 2004-06-17 Panzer Scott R Molecules for diagnostics and therapeutics
DE10326526B4 (de) * 2002-06-22 2006-06-22 Spinner Gmbh Koaxialer Steckverbinder
US7101679B2 (en) 2003-11-25 2006-09-05 Mayo Foundation For Medical Education And Research Marker for neuromyelitis optica

Also Published As

Publication number Publication date
US20090143710A1 (en) 2009-06-04
JP2007518068A (ja) 2007-07-05
CN1910456A (zh) 2007-02-07
US7947254B2 (en) 2011-05-24
US20120219969A1 (en) 2012-08-30
IN2014DN05011A (de) 2015-07-10
US20050112116A1 (en) 2005-05-26
US7101679B2 (en) 2006-09-05
US20080145870A1 (en) 2008-06-19
JP4538464B2 (ja) 2010-09-08
EP1700120B1 (de) 2009-03-04
DE602004019812D1 (de) 2009-04-16
US8524508B2 (en) 2013-09-03
US20140314796A1 (en) 2014-10-23
EP1700120A4 (de) 2007-11-14
WO2005051178A2 (en) 2005-06-09
EP1700120A2 (de) 2006-09-13
ES2320006T3 (es) 2009-05-18
CN1910456B (zh) 2011-04-13
WO2005051178A3 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
ATE424560T1 (de) Marker für neuromyelitis optica
EP1912674A4 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
ATE414535T1 (de) Trägerproteine für impfstoffe
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
SE0301650D0 (sv) Novel compounds
ITTO20020117A0 (it) Apparecchiatura per prove tribologiche.
DE60219633D1 (de) LÄNGLICHER KANISTER FÜr EINEN AUTOMATISIERTEN MIKROBIOLOGISCHEN ANALYSATOR
DE60326773D1 (de) Peptid-deformylase-hemmer
NO20025738D0 (no) Metode
WO2004083241A3 (en) Btc-interacting proteins and use thereof
FI20031191A7 (fi) Monoamiinin takaisinoton estäjä
TW200700089A (en) Recombinant protein comprising starch binding domain and use thereof
AU2003293556A1 (en) Methods of diagnosing and treating cancer
DE60207833D1 (de) Peptiddeformylase-hemmer
ATE548037T1 (de) Peptid-deformylase-hemmer
IS7441A (is) Peptíðdeformýlasatálmar
DE60232650D1 (de) Peptiddeformylaseinhibitoren
ATE346915T1 (de) Hybrid topoisomerasen und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties